Interpretive criteria for testing susceptibility of staphylococci to mupirocin
about
Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureusHigh-level mupirocin resistance within methicillin-resistant Staphylococcus aureus pandemic lineagesCommunity-acquired pneumonia due to pandemic A(H1N1)2009 influenzavirus and methicillin resistant Staphylococcus aureus co-infection.Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trialOutbreak of mupirocin-resistant staphylococci in a hospital in Warsaw, Poland, due to plasmid transmission and clonal spread of several strains.Mupirocin prophylaxis against methicillin-susceptible, methicillin-resistant, or vancomycin-intermediate Staphylococcus epidermidis vascular-graft infection.Evolution and diversity of community-associated methicillin-resistant Staphylococcus aureus in a geographical region.The molecular epidemiology of the highly virulent ST93 Australian community Staphylococcus aureus strain.Mupirocin resistance in nasal carriage of Staphylococcus aureus among healthcare workers of a tertiary care rural hospital.Characteristics of Staphylococcus aureus strains isolated in Poland in 1996 to 2004 that were deficient in species-specific proteinsMupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial.Community-associated methicillin-resistant Staphylococcus aureus, Minnesota, 2000-2003.A multidrug-resistant Staphylococcus epidermidis clone (ST2) is an ongoing cause of hospital-acquired infection in a Western Australian hospital.Methicillin-resistant Staphylococcus aureus clones, Western AustraliaTargeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial.Mupirocin - Are we in danger of losing it?Methicillin resistant and susceptible Staphylococcus aureus: Appraising therapeutic approaches in the Northwest of IranCurrent and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns.Differentiation of clonal complex 59 community-associated methicillin-resistant Staphylococcus aureus in Western Australia.Screening for Mupirocin Resistance in Staphylococcus.Screening of methicillin-resistant Staphylococcus aureus in healthcare workers and students and its susceptibility to mupirocin in a tertiary care teaching hospital in South India.Resistance pattern of mupirocin in methicillin-resistant Staphylococcus aureus in trauma patients and comparison between disc diffusion and E-test for better detection of resistance in low resource countries.Multicenter study to determine disk diffusion and broth microdilution criteria for prediction of high- and low-level mupirocin resistance in Staphylococcus aureus.Panton-Valentine leukocidin-positive MRSA, Shanghai.Quality control guidelines for MIC susceptibility testing of omiganan pentahydrochloride (MBI 226), a novel antimicrobial peptide.Evaluation of Methicillin-Resistance Rates among Community-associated Infections in Korean Military Personnel
P2860
Q24550651-61C56916-4F07-4006-B5ED-6D23DB2B4151Q30356535-A917231F-BF91-46A9-A676-A9153A5F8C04Q30384680-F7293F27-6C79-494D-A5A5-AE81D81680EFQ33952282-737A9934-B8D2-4B6D-93FD-0467A24243A7Q33962382-6F7857E4-DD5F-4069-AA62-8778266023E9Q33980808-96AF6363-27DD-44C0-8EA8-9C3CA72BA4A8Q34033940-E8EDD1C1-918E-4F12-845F-989D03ED154DQ34382749-9DB9C590-EA54-4C84-A84C-5C59EF44CECBQ34546013-429A1CBF-E651-4507-92FD-D5EE2BBF4C15Q35220832-492685D2-6BC3-4E9C-B15A-64D9F783EC4BQ35870407-4F90EFE6-D657-4BEF-BAB9-8777A3F30CBBQ36006683-4B3E5930-3606-4F11-BEB5-8712D611147DQ36022986-BFF49FB6-FA60-4FB6-AC9A-35F4E8C81ACCQ36026397-6F33DE11-105A-453F-9D22-7D0CA6A23D33Q36095019-0347CD73-13C2-4551-A773-5288B3469194Q36170529-D20A6BA9-F7A1-482E-B54C-ABB9DBCB6AFEQ36624479-9E8C9631-8A92-471C-BFFD-CACEBB1F2A00Q38673550-879BE8A1-87ED-4E48-9F45-7C6AFBE2DF57Q40335372-D75AC715-E5D5-4055-8E38-B5B49DC79C99Q40914468-C7E49751-F9AD-4BE9-8FED-3961B18127A3Q41649215-21EB37C0-215E-4C41-AC57-2647625C2CB4Q41811526-4D59EEDC-EB1B-404F-80A5-7345071FE281Q41846268-61691A02-81A1-40A7-8A49-E54C74C4921AQ42553310-8BC8FC43-DE04-4C51-B62A-0F1BDC8E9EBDQ43179734-BF4EC5FE-CBB0-4299-A6E3-E4A0CCB51CD8Q57213703-DD4EB715-0D1D-4FEE-B452-AF151BA79ABF
P2860
Interpretive criteria for testing susceptibility of staphylococci to mupirocin
description
1997 nî lūn-bûn
@nan
1997 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Interpretive criteria for testing susceptibility of staphylococci to mupirocin
@ast
Interpretive criteria for testing susceptibility of staphylococci to mupirocin
@en
type
label
Interpretive criteria for testing susceptibility of staphylococci to mupirocin
@ast
Interpretive criteria for testing susceptibility of staphylococci to mupirocin
@en
prefLabel
Interpretive criteria for testing susceptibility of staphylococci to mupirocin
@ast
Interpretive criteria for testing susceptibility of staphylococci to mupirocin
@en
P2093
P2860
P356
P1476
Interpretive criteria for testing susceptibility of staphylococci to mupirocin
@en
P2093
P2860
P304
P356
10.1128/AAC.41.5.1137
P407
P577
1997-05-01T00:00:00Z